Table 1 Robust Mendelian randomization analysis of association between the anti-VZV IgG levels and Parkinson’s disease progress.

From: Impact of anti-VZV IgG levels on Parkinson’s disease risk and progression: a Mendelian randomization analysis

Outcome

MR Egger

Weighted median

Simple mode

Weighted mode

Beta or OR (95% CI)

P-value

Beta or OR (95% CI)

P-value

Beta or OR (95% CI)

P-value

Beta or OR (95% CI)

P-value

Constipation

1.980 (0.567, 6.911)

0.300

1.762 (1.060, 2.930)

0.029

1.925 (0.966, 3.834)

0.080

1.871 (0.970, 3.610)

0.079

Dementia

1.397 (0.478, 4.082)

0.549

0.789 (0.507, 1.226)

0.292

0.706 (0.350, 1.423)

0.344

0.764 (0.397, 1.468)

0.430

Depression

0.675 (0.235, 1.934)

0.476

1.091 (0.716, 1.662)

0.686

1.037 (0.546, 1.968)

0.913

1.059 (0.544, 2.062)

0.869

Dyskinesias

43.056(0.002, 788253.468)

0.494

0.441 (0.140, 1.388)

0.162

0.336 (0.065, 1.727)

0.248

0.366 (0.074, 1.798)

0.271

HY3

19.172 (3.581, 102.646)

0.004

2.657 (1.297, 5.445)

0.008

2.186 (0.583, 8.198)

0.264

2.310 (0.664, 8.039)

0.208

Hyposmia

0.430 (0.134, 1.385)

0.177

0.602 (0.377, 0.962)

0.034

0.606 (0.283, 1.298)

0.215

0.601 (0.309, 1.169)

0.152

Insomnia

1.779 (0.630, 5.022)

0.293

1.709 (1.123, 2.601)

0.012

1.645 (0.858, 3.153)

0.152

1.752 (0.944, 3.252)

0.094

Motor fluctuation

1.048 (0.533, 2.061)

0.893

1.108 (0.830, 1.481)

0.486

1.114 (0.707, 1.757)

0.647

1.129 (0.756, 1.688)

0.560

RBD

3.873 (0.698, 21.500)

0.142

1.937 (0.949, 3.955)

0.069

2.082 (0.626, 6.927)

0.249

2.273 (0.864, 5.980)

0.116

Restless Legs

7.452 (1.138, 48.798)

0.056

3.010 (1.334, 6.789)

0.008

2.256 (0.679, 7.493)

0.205

3.2500.834, 12.660)

0.111

UPDRS total

1.187 (0.823, 1.712)

0.378

1.115 (0.968, 1.283)

0.131

1.219 (0.939, 1.582)

0.163

1.200 (0.952, 1.513)

0.149

UPDRS1

0.321 (0.210, 0.490)

 < 0.001

0.639 (0.522, 0.781)

 < 0.001

0.551 (0.390, 0.778)

0.004

0.559 (0.394, 0.793)

0.006

UPDRS2

0.709 (0.441, 1.139)

0.193

0.918 (0.752, 1.120)

0.399

0.859 (0.622, 1.186)

0.379

0.864 (0.643, 1.161)

0.358

UPDRS3

0.786 (0.548, 1.127)

0.209

0.885 (0.764, 1.025)

0.102

0.894 (0.719, 1.112)

0.330

0.873 (0.710, 1.073)

0.216

UPDRS4

1.175 (0.788, 1.752)

0.443

1.105 (0.945, 1.291)

0.210

1.098 (0.886, 1.360)

0.408

1.101 (0.863, 1.404)

0.451

MMSE

1.274 (0.663, 2.447 )

0.482

1.118 (0.863, 1.447)

0.398

1.178 (0.772, 1.797)

0.462

1.143 (0.781, 1.674)

0.502

MoCA

1.297 (0.225, 7.475)

0.775

1.557 (0.779, 3.111)

0.210

1.315 (0.425, 4.069)

0.642

1.293 (0.439, 3.811)

0.648

SEADL

0.131 (0.004, 4.164)

0.270

0.366 (0.084, 1.589)

0.180

0.216 (0.020, 2.315)

0.226

0.260 (0.030, 2.243)

0.241

  1. HY3 Hoehn-Yahr stage 3 or more; RBD Rapid eye movement sleep behavioral disorder; UPDRS Unified Parkinson’s disease rating scale; MMSE Mini-mental state examination; MOCA Montreal cognitive assessment; SEADL Modified Schwab and UK Scale of Activities of Daily Living.
Back to article page